TMCnet

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

MIAMI, May 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic ...
American Lung Association

Chronic Lung Disease

What Is Chronic Lung Disease? A chronic lung disease is a type of disease that prevents the lungs and respiratory system from working correctly. The main job of the respiratory system is to take in ...

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart ...

Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and ...
thorax.bmj

British Thoracic Society Clinical Statement on pulmonary rehabilitation

1 Royal Brompton & Harefield Hospitals, Guy’s and St.Thomas’ NHS Foundation Trust, London, UK Since the Guideline, there is deeper understanding of referral characteristics, outcome measures, patient ...

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart ...

Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced ...
Pulmonary Hypertension News

Treprostinil shows lasting benefits for children with lung-related PH

Treatment with treprostinil led to significant and sustained improvements in children with PH associated with lung disease, ...